[1] Makino N, Nakamura Y, Yashiro M, et al. Descriptive epidemiology of Kawasaki disease in Japan, 2011-2012:from the results of the 22nd nationwide survey[J]. J Epidemiol, 2015, 25(3):239-245.
[2] Kuroda M, Sakaue H. Role of vitamin D and calcium in obesity and type 2 diabetes[J]. Clin Calcium, 2016, 26(3):349-354.
[3] Aguirre M, Manzano M, Salas Y, et al. Vitamin D deficiency in patients admitted to the general ward with breast, lung, and colorectal cancer in Buenos Aires, Argentina[J]. Arch Osteoporos, 2016, 11:4.
[4] Desai CK, Huang J, Lokhandwala A, et al. The role of vitamin supplementation in the prevention of cardiovascular disease events[J]. Clin Cardiol, 2014, 37(9):576-581.
[5] Li YC, Chen Y, Liu W, et al. MicroRNA-mediated mechanism of vitamin D regulation of innate immune response[J]. J Steroid Biochem Mol Biol, 2014, 144 Pt A:81-86.
[6] Pilon C, Urbanet R, Williams TA, et al. 1α,25-Dihydroxyvitamin D₃ inhibits the human H295R cell proliferation by cell cycle arrest:a model for a protective role of vitamin D receptor against adrenocortical cancer[J]. J Steroid Biochem Mol Biol, 2014, 140:26-33.
[7] Ricciardi CJ, Bae J, Esposito D, et al. 1,25-Dihydroxyvitamin D3/vitamin D receptor suppresses brown adipocyte differentiation and mitochondrial respiration[J]. Eur J Nutr, 2015, 54(6):1001-1012.
[8] Durk MR, Fan J, Sun H, et al. Vitamin D receptor activation induces P-glycoprotein and increases brain efflux of quinidine:an intracerebral microdialysis study in conscious rats[J]. Pharm Res, 2015, 32(3):1128-1140.
[9] Oz F, Cizgici AY, Oflaz H, et al. Impact of vitamin D insufficiency on the epicardial coronary flow velocity and endothelial function[J]. Coron Artery Dis, 2013, 24(5):392-397.
[10] 张远达, 李荣敏, 冀超玉, 等. 川崎病患儿25-羟基维生素D3水平变化及意义[J]. 中国当代儿科杂志, 2016, 18(3):211-214.
[11] Stagi S, Rigante D, Lepri G, et al. Severe vitamin D deficiency in patients with Kawasaki disease:a potential role in the risk to develop heart vascular abnormalities?[J]. Clin Rheumatol, 2016, 35(7):1865-1872.
[12] Schoenmakers I, Gousias P, Jones KS, et al. Prediction of winter vitamin D status and requirements in the UK population based on 25(OH) vitamin D half-life and dietary intake data[J]. J Steroid Biochem Mol Biol, 2016. doi:10.1016/j.jsbmb.2016.03.015.[Epub ahead of print].
[13] Camargo CA Jr, Ganmaa D, Sidbury R, et al. Randomized trial of vitamin D supplementation for winter-related atopic dermatitis in children[J]. J Allergy Clin Immunol, 2014, 134(4):831-835.
[14] 上官文, 杜忠东, 杨海明, 等. 丙种球蛋白对川崎病小鼠心脏核因子κB与MMP-9表达及活性的影响[J].中华医学杂志, 2014, 94(12):938-943.
[15] Sakata K, Hamaoka K, Ozawa S, et al. Matrix metalloproteinase-9 in vascular lesions and endothelial regulation in Kawasaki disease[J]. Cric J, 2010, 74(8):1670-1675.
[16] Yin W, Wang X, Ding Y, et al. Expression of nuclear factor-κBp65 in mononuclear cells in Kawasaki disease and its relation to coronary artery lesions[J]. Indian J Pediatr, 2011, 78(11):1378-1382.
[17] Senzaki H. The pathophysiology of coronary artery aneurysms in Kawasaki disease:role of matrix metalloproteinases[J]. Arch Dis Child, 2006, 91(10):847-851.
[18] Wang Y, Wang W, Gong F, et al. Evaluation of intravenous immunoglobulin resistance and coronary artery lesions in relation to Th1/Th2 cytokine profiles in patients with Kawasaki disease[J]. Arthritis Rheum, 2013, 65(3):805-814.
[19] Lv YW, Wang J, Sun L, et al. Understanding the pathogenesis of Kawasaki disease by network and pathway analysis[J]. Comput Math Methods Med, 2013, 2013:989307.
[20] Suzuki Y, Ichiyama T, Ohsaki A, et al. Anti-inflammatory effect of 1alpha,25-dihydroxyvitamin D(3) in human coronary arterial endothelial cells:Implication for the treatment of Kawasaki disease[J]. J Steroid Biochem Mol Biol, 2009, 113(1-2):134-138.
[21] Kudo K, Hasegawa S, Suzuki Y, et al. 1α,25-Dihydroxyvitamin D(3) inhibits vascular cellular adhesion molecule-1 expression and interleukin-8 production in human coronary arterial endothelial cells[J]. J Steroid Biochem Mol Biol, 2012, 132(3-5):290-294.
[22] Mittal A, Gupta MD, Meennahalli Palleda G, et al. Relationship of plasma adiponectin levels with acute coronary syndromes and coronary lesion severity in north Indian population[J]. ISRN Cardiol, 2013, 2013:854815.
[23] 黄秒, 董国庆, 蒋红英, 等. 川崎病患儿血清脂联素水平的变化[J]. 中国当代儿科杂志, 2015, 17(1): 35-39.
[24] Ko TM, Kuo HC, Chang JS, et al. CXCL10/IP-10 is a biomarker and mediator for Kawasaki disease[J]. Circ Res, 2015, 116(5):876-883.
[25] Feng S, Yadav SK, Gao F, et al. Plasma levels of monokine induced by interferon-gamma/chemokine (C-X-X motif) ligand 9, thymus and activation-regulated chemokine/chemokine (C-C motif) ligand 17 in children with Kawasaki disease[J]. BMC Pediatr, 2015, 15:109.
[26] Selvaraj P, Harishankar M, Singh B, et al. Effect of vitamin D3 on chemokine expression in pulmonary tuberculosis[J]. Cytokine, 2012, 60(1):212-219.
[27] Wang X, Chen Q, Pu H, et al. Adiponectin improves NF-κB-mediated inflammation and abates atherosclerosis progression in apolipoprotein E-deficient mice[J]. Lipids Health Dis, 2016, 15:33.
[28] Stokic E, Kupusinac A, Tomic-Naglic D, et al. Vitamin D and dysfunctional adipose tissue in obesity[J]. Angiology, 2015, 66(7):613-618.
[29] Walker GE, Ricotti R, Roccio M, et al. Pediatric obesity and vitamin D deficiency:a proteomic approach identifies multimeric adiponectin as a key link between these conditions[J]. PLoS One, 2014, 9(1):e83685.
[30] Ding YY, Ren Y, Feng X, et al. Correlation between brachial artery flow-mediated dilation and endothelial microparticle levels for identifying endothelial dysfunction in children with Kawasaki disease[J]. Pediatr Res, 2014, 75(3):453-458.
[31] 刘俊峰, 杜忠东, 陈植, 等. 川崎病模型小鼠内皮祖细胞的状态[J]. 中华医学杂志, 2012, 92(22):1560-1564.
[32] Chen Z, DU ZD, Liu JF, et al. Endothelial progenitor cell transplantation ameliorates elastin breakdown in a Kawasaki disease mouse model[J]. Chin Med J(Engl), 2012, 125(13):2295-2301.
[33] Chen X, Chen Q, Wang L, et al. Ghrelin induces cell migration through GHSR1a-mediated PI3K/Akt/eNOS/NO signaling pathway in endothelial progenitor cells[J]. Metabolism, 2013, 62(5):743-752.
[34] Chan YH, Lau KK, Yiu KH, et al. Vascular protective effects of statin-related increase in serum 25-hydroxyvitamin D among high-risk cardiac patients[J]. J Cardiovasc Med (Hagerstown), 2015, 16(1):51-58.
[35] Martínez-Miguel P, Valdivielso JM, Medrano-Andrés D, et al. The active form of vitamin D, calcitriol, induces a complex dual upregulation of endothelin and nitric oxide in cultured endothelial cells[J]. Am J Physiol Endocrinol Metab, 2014, 307(12):E1085-E1096.
[36] Reynolds JA, Haque S, Williamson K, et al. Vitamin D improves endothelial dysfunction and restores myeloid angiogenic cell function via reduced CXCL-10 expression in systemic lupus erythematosus[J]. Sci Rep, 2016, 6:22341.
[37] Yahata T, Suzuki C, Yoshioka A, et al. Platelet activation dynamics evaluated using platelet-derived microparticles in Kawasaki disease[J]. Circ J, 2014, 78(1):188-193.
[38] Laurito M, Stazi A, Delogu AB, et al. Endothelial and platelet function in children with previous Kawasaki disease[J]. Angiology, 2014, 65(8):716-722.
[39] Silvagno F, De Vivo E, Attanasio A, et al. Mitochondrial localization of vitamin D receptor in human platelets and differentiated megakaryocytes[J]. PLoS One, 2010, 5(1):e8670.
[40] Stach K, Kälsch AI, Nguyen XD, et al. 1α,25-dihydroxyvitamin D3 attenuates platelet activation and the expression of VCAM-1 and MT1-MMP in human endothelial cells[J]. Cardiology, 2011, 118(2):107-115.
[41] Cumhur Cure M, Cure E, Yuce S, et al. Mean platelet volume and vitamin D level[J]. Ann Lab Med, 2014, 34(2):98-103.
[42] Uysal HB, Dağlı B, Akgüllü C, et al. Blood count parameters can predict the severity of coronary artery disease[J]. Korean J Intern Med, 2016, 31(6):1093-1100.
[43] López-Farré AJ, Modrego J, Azcona L, et al. Nitric oxide from mononuclear cells may be involved in platelet responsiveness to aspirin[J]. Eur J Clin Invest, 2014, 44(5):463-469.
[44] Renauer P, Coit P, Sawalha AH. Epigenetics and vasculitis:a comprehensive review[J]. Clin Rev Allergy Immunol, 2016, 50(3):357-366.
[45] Khor CC, Davila S, Breunis WB, et al. Genome-wide association study identifies FCGR2A as a susceptibility locus for Kawasaki disease[J]. Nat Genet, 2011, 43(12):1241-1246.
[46] Kuo HC, Chang JC, Kuo HC, et al. Identification of an association between genomic hypomethylation of FCGR2A and susceptibility to Kawasaki disease and intravenous immunoglobulin resistance by DNA methylation array[J]. Arthritis Rheumatol, 2015, 67(3):828-836.
[47] Kuo HC, Hsu YW, Wu MS, et al. FCGR2A promoter methylation and risks for intravenous immunoglobulin treatment responses in Kawasaki disease[J]. Mediators Inflamm, 2015, 2015:564625.
[48] Zhu H, Bhagatwala J, Huang Y, et al. Race/ethnicity-specific association of vitamin D and global DNA methylation:cross-sectional and interventional findings[J]. PLoS One, 2016, 11(4):e0152849.